Fig. 3
From: AAV-NRIP gene therapy ameliorates motor neuron degeneration and muscle atrophy in ALS model mice
AAV-NRIP gene therapy improves locomotor activity in SOD1 G93A mice. A Total distance moved by SOD1 G93A mice with AAV-GFP or AAV-NRIP treatment. From the age of 100 days (post-infection day 40) to 147 days (post-infection day 87), the movement of the mice for 10 min was recorded using EthoVision Video Tracking Software (Noldus). The total distance moved (total distance mice traveled in the box) was measured during the test. Data are presented as mean ± SEM. *P = 0.019 at the age of 120 days; *P = 0.0452 at the age of 126 days; *P = 0.0494 at the age of 133 days; ns, no significance; one-way ANOVA with Tukey’s post hoc test. B Rearing frequency (frequency at which the mice stand on their hindlimbs in the box). The number of rearing was measured from the age of 100 days to 147 days. Data are presented as mean ± SEM. *P = 0.0496 at the age of 126 days; *P = 0.0382 at the age of 133 days; ns, no significance; one-way ANOVA with Tukey’s post hoc test